MTOR and tuberous sclerosis: There is abundant supportive evidence for the efficacy of both drugs in TSC patients, namely, for the therapeutic approach of some of its manifestations, but the fact is that there are not, to date, clinical trials directly comparing those mTOR inhibitors (in TSC, oncology and transplantation).